Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Aug 2016
At a glance
- Drugs Naloxone (Primary)
- Indications Bulimia nervosa; Cocaine abuse; Drug abuse; Eating disorders; Opioid abuse
- Focus Pharmacodynamics
- 01 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 08 Jun 2016 Status changed from not yet recruiting to recruiting.
- 16 Mar 2016 According to Opiant Pharmaceuticals media release, dosing is expected to initiate in 1Q17 in eating disorders patients.